Hosseinali Asgharian

Hosseinali Asgharian

Auto-generated profile, based on publicly available information

Hosseinali Asgharian

Department of Biochemistry and Biophysics, University of California, San Francisco, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
MPMaria C. Passarelli
Maria C. Passarelli
APAlexandra M. Pinzaru
Alexandra M. Pinzaru
HAHosseinali Asgharian
Hosseinali Asgharian
MLMaria V. Liberti
Maria V. Liberti
SHSøren Heissel
Søren Heissel
STSohail F. Tavazoie
Sohail F. Tavazoie

8 May 2023 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
ANAlbertas Navickas
Albertas Navickas
HAHosseinali Asgharian
Hosseinali Asgharian
JWJuliane Winkler
Juliane Winkler
LFLisa Fish
Lisa Fish
KGKristle Garcia
Kristle Garcia
HGHani Goodarzi
Hani Goodarzi
Cancer cells often co-opt post-transcriptional regulatory mechanisms to achieve pathologic expression of gene networks that drive metastasis. Translational control is a major regulatory hub in oncogenesis; however, its effects on cancer progression remain poorly understood. Here, to address this, we used ribosome profiling to compare genome-wide translation efficiencies of poorly and highly metastatic breast cancer cells and patient-derived xenografts. We developed dedicated regression-based methods to analyse ribosome profiling and alternative polyadenylation data, and identified heterogeneous nuclear ribonucleoprotein C (HNRNPC) as a translational controller of a specific mRNA regulon. We found that HNRNPC is downregulated in highly metastatic cells, which causes HNRNPC-bound mRNAs to undergo 3′ untranslated region lengthening and, subsequently, translational repression. We showed that modulating HNRNPC expression impacts the metastatic capacity of breast cancer cells in xenograft mouse models. In addition, the reduced expression of HNRNPC and its regulon is associated with the worse prognosis in breast cancer patient cohorts.

5 October 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
ANAlbertas Navickas
Albertas Navickas
HAHosseinali Asgharian
Hosseinali Asgharian
JWJuliane Winkler
Juliane Winkler
LFLisa Fish
Lisa Fish
KGKristle Garcia
Kristle Garcia
HGHani Goodarzi
Hani Goodarzi
Cancer cells often co-opt post-transcriptional regulatory mechanisms to achieve pathologic expression of gene networks that drive metastasis. Translational control is a major regulatory hub in oncogenesis, however its effects on cancer progression remain poorly understood. To address this, we used ribosome profiling to compare genome-wide translation efficiencies of poorly and highly metastatic breast cancer cells and patient-derived xenografts. We developed novel regression-based methods to analyze ribosome profiling and alternative polyadenylation data, and identified HNRNPC as a translational controller of a specific mRNA regulon. Mechanistically, HNRNPC, in concert with PABPC4, binds near to poly(A) signals, thereby governing the alternative polyadenylation of a set of mRNAs. We found that HNRNPC and PABPC4 are downregulated in highly metastatic cells, which causes HNRNPC-bound mRNAs to undergo 3’ UTR lengthening and subsequently, translational repression. We showed that modulating HNRNPC expression impacts the metastatic capacity of breast cancer cells in xenograft mouse models. We also found that a small molecule, previously shown to induce a distal-to-proximal poly(A) site switching, counteracts the HNRNPC-PABPC4 driven deregulation of alternative polyadenylation and decreases the metastatic lung colonization by breast cancer cells in vivo .

14 December 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
AGAlex Y. Ge
Alex Y. Ge
AAAbolfazl Arab
Abolfazl Arab
RDRaymond Dai
Raymond Dai
ANAlbertas Navickas
Albertas Navickas
LFLisa Fish
Lisa Fish
LGLuke A. Gilbert
Luke A. Gilbert
SUMMARY: The search for new approaches in cancer therapy requires a mechanistic understanding of cancer vulnerabilities and anti-cancer drug mechanisms of action. Problematically, some effective therapeutics target cancer vulnerabilities that have poorly defined mechanisms of anti-cancer activity. One such drug is decitabine, a frontline therapeutic approved for the treatment of high-risk acute myeloid leukemia (AML). Decitabine is thought to kill cancer cells selectively via inhibition of DNA methyltransferase enzymes, but the genes and mechanisms involved remain unclear. Here, we apply an integrated multiomics and CRISPR functional genomics approach to identify genes and processes associated with response to decitabine in AML cells. Our integrated multiomics approach reveals RNA dynamics are key regulators of DNA hypomethylation induced cell death. Specifically, regulation of RNA decapping, splicing and RNA methylation emerge as important regulators of cellular response to decitabine.

16 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
BWBrian J Woo
Brian J Woo
RMRuhollah Moussavi-Baygi
Ruhollah Moussavi-Baygi
HKHeather Karner
Heather Karner
MKMehran Karimzadeh
Mehran Karimzadeh
KGKristle Garcia
Kristle Garcia
HGHani Goodarzi
Hani Goodarzi
Large-scale sequencing efforts of thousands of tumor samples have been undertaken to understand the mutational landscape of the coding genome. However, the vast majority of germline and somatic variants occur within non-coding portions of the genome. These genomic regions do not directly encode for specific proteins, but can play key roles in cancer progression, for example by driving aberrant gene expression control. Here, we designed an integrative computational and experimental framework to identify recurrently mutated non-coding regulatory regions that drive tumor progression. Application of this approach to whole-genome sequencing (WGS) data from a large cohort of metastatic castration-resistant prostate cancer (mCRPC) revealed a large set of recurrently mutated regions. We used (i) in silico prioritization of functional non-coding mutations, (ii) massively parallel reporter assays, and (iii) in vivo CRISPR-interference (CRISPRi) screens in xenografted mice to systematically identify and validate driver regulatory regions that drive mCRPC. We discovered that one of these enhancer regions, GH22I030351, acts on a bidirectional promoter to simultaneously modulate expression of U2-associated splicing factor SF3A1 and chromosomal protein CCDC157. We found that both SF3A1 and CCDC157 are promoters of tumor growth in xenograft models of prostate cancer. We nominated a number of transcription factors, including SOX6, to be responsible for higher expression of SF3A1 and CCDC157. Collectively, we have established and confirmed an integrative computational and experimental approach that enables the systematic detection of non-coding regulatory regions that drive the progression of human cancers.

22 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
LELisa B. Earnest-Noble
Lisa B. Earnest-Noble
DHDennis Hsu
Dennis Hsu
HAHosseinali Asgharian
Hosseinali Asgharian
MNMandayam Nandan
Mandayam Nandan
MPMaria C. Passarelli
Maria C. Passarelli
STSohail F. Tavazoie
Sohail F. Tavazoie
The human genome contains 61 codons that encode for the 20 amino acids. The synonymous codons of a given amino acid are decoded by a set of transfer RNAs (tRNAs) called isoacceptors. We report the surprising observation that two isoacceptor tRNAs that decode synonymous codons are modulated in opposing directions during breast cancer progression. Specifically, tRNA Ile UAU is upregulated, whereas tRNA Ile GAU is repressed as breast cancer cells attained enhanced metastatic capacity. Functional studies revealed that tRNA Ile UAU promoted and tRNA Ile GAU suppressed metastatic colonization. The expression of these tRNAs mediated opposing effects on codon-dependent translation of growth promoting genes. Consistent with this, multiple mitotic gene sets in the human genome are significantly enriched in the codon cognate to the growth-promoting tRNA Ile UAU and significantly depleted of the codon cognate to the growth-suppressive tRNA Ile GAU . Our findings uncover a specific isoacceptor tRNA pair that act in opposition—divergently regulating genes that contribute to growth and a disease phenotype. The degeneracy of the genetic code can thus be biologically exploited by human cancer cells via tRNA isoacceptor shifts that facilitate the transition towards a growth-promoting state.